From the Professor..., page-157

Like I said, bile duct might be very rare but it's also aggressive form of cancer. CF33 has been proven to work on a lot of solid cancer in lab, is this the same as CG0070??? What do you think CF33 will do to other cancer which are less aggressive???? IMU received Fast Track Designation for bile duct but the clinical trial are focus on a variety of solid cancer which is were the massive market potential lies, the market for just cholangiocarcinoma won't value IMU at a $10B+ MC but what do you think is the valuation for treating a lot of solid cancer will be???? Don't you think this will perk all the BP's interest????

This says CG0070 is currently in Ph3 clinical trial, IMU is moving very fast with over $100M in funding don't you think????

https://ascopubs.org/doi/10.1200/JCO.2022.40.6_suppl.TPS598